knowcompoundsfucoxanthin
Specimen compound organic compound
Fucoxanthin
An epoxycarotenol that is found in brown seaweed and which exhibits anti-cancer, anti-diabetic, anti-oxidative and neuroprotective properties.”
- Formula
- C42H58O6
- Molar mass
- 658.92 g/mol
- ChEBI
- CHEBI:5186
- InChIKey
- SJWWTRQNNRNTPU-XJUZQKKNSA-N
↓ lowered 1 finding in 1 endpoint · – no difference found 1 in 1
01 · the evidence, ordered
What the evidence says
- Strong
- 0
- Moderate
- 0
- Limited
- 0
- Very limited
- 3
- Insufficient
- 3
Fucoxanthin
Most findings
- Alanine aminotransferase×2
- EPHB2×1
- KEAP1×1
- SIRT1×1
- TLR4×1
36 compounds on the outer ring, not drawn
Keys
← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it
02 · contested · 1 endpoint
Where the findings disagree
012 findings
Alanine aminotransferase
03 · findings
What fucoxanthin moved, and by how much
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
6 shown
- TLR4Moved: inhibitsEvidence: Very limitedPaper: PMID 354478992022
- Who
- Human Chang liver cell line, FFA-induced NAFLD cell model, fucoxanthin group
- Dose studied
- not reported
The expression of TLR4 and its downstream proteins myeloid differentiation factor 88 (MyD88), p-IκBα, and p-NF-κBp65 was significantly upregulated in the FFA group, and was significantly inhibited by treatment with fucoxanthin.”
Quoted verbatim from Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway.in vitro · not in humansPermalink - EPHB2Moved: inhibitsEvidence: Very limitedPaper: PMID 336737042021
- Who
- RAW264.7 murine macrophage cells stimulated with sRANKL or TNF-alpha/IL-6
- Dose studied
- 0, 1, 2.5 and 5 uM FX
The treatment of RAW264.7 cells with FX significantly reduced the phosphorylation of ERK and p38 in a concentration-dependent manner.”
Quoted verbatim from Fucoxanthin Suppresses Osteoclastogenesis via Modulation of MAP Kinase and Nrf2 Signaling.in vitro · not in humans · 4 daysPermalink - KEAP1Moved: bindsEvidence: Very limitedPaper: PMID 337773212021
- Who
- purified human Keap1 protein, biolayer interferometry
- Dose studied
- not reported
shows that FUC bound to Keap1 protein in a dose-dependent manner, with constant of KD = 5.16 E − 5, constant of Kon = 6.73 E + 2, and constant of Koff = 3.47 E − 2.”
Quoted verbatim from Fucoxanthin Prevents 6-OHDA-Induced Neurotoxicity by Targeting Keap1.in vitro · not in humansPermalink - SIRT1Moved: activatesEvidence: InsufficientPaper: PMID 338650172021
- Who
- C2C12 myotubes with dexamethasone-induced atrophy
- Dose studied
- fucoxanthin 10 μM
Through activating SIRT1, fucoxanthin inhibits forkhead box O (FoxO) transcriptional activity to reduce protein degradation, induces autophagy to enhance degraded protein clearance, promotes mitochondrial function and diminishes apoptosis.”
Quoted verbatim from Fucoxanthin rescues dexamethasone induced C2C12 myotubes atrophy.in vitro · not in humansPermalink - Alanine aminotransferasecontestedMoved: lowersEvidence: InsufficientPaper: PMID 311379222019
- Who
- female C57BL/6J mice fed a high-fat diet for 6 weeks; FX arm compared with the high-fat-diet control arm
- Dose studied
- FX 0.1 mg/kg/day
FX and PE-M + CLA treatment significantly decreased ALT levels, whereas PE treatment slightly decreased ALT levels, compared with those in the HFD group.”
Quoted verbatim from Anti-Obesity Effect of Standardized Extract of Microalga Phaeodactylum tricornutum Containing Fucoxanthin.animal · not in humans · 6 weeksPermalink - Alanine aminotransferasecontestedMoved: no difference foundEvidence: InsufficientPaper: PMID 356840792022
- Who
- C57BL/6J mice, pooled across HFC (high-fat/high-sucrose/high-cholesterol) and HFS (high-fat/high-sucrose) diet-induced obesity models, FCX-supplemented diet vs same diet without FCX
- Dose studied
- 0.015% or 0.03% w/w FCX in HFC diet, 12 weeks; 0.01% w/w FCX in HFS diet, 8 weeks
No significant differences were present in liver triglyceride and total cholesterol, hepatic fat accumulation, and serum alanine aminotransferase levels between control and FCX-fed mice regardless of whether they were on an HFC or HFS diet.”
Quoted verbatim from Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity.animal · not in humansPermalink
No row matches these filters.
No dose is advised.
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
04 · identity
Structure
- Charge
- 0
- 3D model
- None at PubChem
- SMILES
- [H]C(=C=C1C(C)(C)C[C@H](OC(C)=O)C[C@@]1(C)O)/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)C(=O)C[C@@]12O[C@]1(C)C[C@@H](O)CC2(C)C
What the reference databases state
- Trials · ClinicalTrials.gov
- 2registered without posted results · 2 past the reporting window
2Registered trials without posted results
Registered, and not reported
- Source
- ClinicalTrials.gov
- Intervention
- fucoxanthin
- Status
- Completed, terminated or suspended
- Results posted
- No
Trials without posted results
2 trials
2 registered trials without posted results · Overdue (FDAAA 801): 2
2 past the window0 within it, or no actual date
- NCT04761406completed2023-05-01industrypast the reporting window
- NCT04851899completed2022-06-01industrypast the reporting window
07 · on the label · 58 products
Labelled products
Source: NIH DSLD · Ingredient: fucoxanthin · 58 products · Declared amount per serving: 0.5–500 mg
30 labels state an amount28 do not
- 1st PhormL-Carnitine Strawberry Mango2.5 mgper 4 gDSLD:262223
- Alpha LionApex Burn Cherry Blaze10%50 mgper 3.25 gDSLD:315549
- AlpileanAlpileanseaweed · 10%amount not statedper 1 capsuleDSLD:299241
- AnoviteLimuzu 6 Natural Fruit Flavoramount not statedper 7.2 gDSLD:319485
- ATS Labs01-02 Enhanced Fat Melting Matrixamount not statedper 1 capsuleDSLD:218923
- Best NaturalsFucoxanthin with Fucoplast5%100 mg · amount not statedper 3 capsulesDSLD:269637
- BiOptimizersBlood Sugar Breakthrough10%amount not statedper 2 capsulesDSLD:320981
- BioSource LabsComplex Diet Dropsamount not statedper 0.5 mLDSLD:313582
- BRI NutritionFucoxanthinFucoxanthin, from Brown Seaweed5 mgper 1 capsuleDSLD:219005
- CellucorStimulant Free Fat Burner75 mgper 1 capsuleDSLD:3679
- CellucorStimulant Free Fat Burner75 mgper 1 capsuleDSLD:3686
- CellucorT7 Extreme75 mgper 1 capsuleDSLD:3684
Show the remaining 46Show the first 12
Label record: NIH Office of Dietary Supplements · CC0
08 · the record
Sources
578
papers screened for fucoxanthin
- admitted
- 6
- read and discarded
- 382
- not read yet
- 190
Sources cited
6 papers · 6 findings
Show every paper citedHide the papers cited
Other names · 3
(3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-β,β-caroten-8-one · (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-β,β-carotene
systematic · (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-β,β-caroten-3'-yl acetate